This product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 cell line, featuring targeted disruption of the ITGA5 gene. The polyclonal nature provides a heterogeneous pool of knockout cells, enabling robust loss-of-function studies without clonal bias. The CRISPR/Cas9-mediated gene disruption of ITGA5 results in loss of integrin alpha-5 expression, allowing researchers to dissect the functional roles of this fibronectin receptor in lung adenocarcinoma biology. This knockout model serves as a critical tool for examining integrin signaling, cell adhesion dynamics, and downstream oncogenic pathways in a disease-relevant cellular context.
The host cell line, A-549, is a widely used human lung adenocarcinoma epithelial cell line originally derived from the tumor of a 58-year-old Caucasian male. These cells exhibit characteristics of alveolar type II pneumocyte-like cells, including lamellar body formation and surfactant production, making them a pertinent in vitro model for studying lung adenocarcinoma pathobiology. The A-549 background retains key genetic and phenotypic features of the tumor microenvironment, such as aberrant proliferation, migration capacity, and angiogenic potential, thereby providing a physiologically relevant platform for investigating integrin-mediated mechanisms driving cancer progression.
ITGA5 encodes the integrin alpha-5 subunit, which pairs exclusively with integrin beta-1 (ITGB1) to form the alpha5beta1 heterodimer, the principal fibronectin receptor. This integrin complex transduces extracellular matrix signals into intracellular cascades through focal adhesion kinase (FAK) and Src family kinases, subsequently activating the PI3K/Akt and MAPK/ERK pathways. ITGA5 expression is regulated by transcription factors such as TGF-beta-induced AP-1, Sp1, and Ets-1. Upon fibronectin binding, alpha5beta1 recruits talin and paxillin to nascent adhesions, facilitating syndecan-4 co-receptor interaction and uPAR-mediated signaling, which collectively promote cell adhesion, migration, proliferation, and survival. Downstream effectors include FAK phosphorylation, Src activation, Akt and ERK1/2 phosphorylation, and induction of matrix metalloproteinases MMP-2/9 and cyclin D1. Disruption of ITGA5 thus abrogates these signaling axes, providing a clean loss-of-function background for mechanistic dissection.
In the A-549 lung adenocarcinoma context, ITGA5 plays a pivotal role in driving tumor cell adhesion to fibronectin-rich stroma, invasion, and metastatic dissemination. Knockout of ITGA5 in these cells impairs anchorage-dependent and -independent growth, reduces migratory competence, and sensitizes cells to anoikis, reflecting the integrin’s essential contribution to pro-survival signaling. This model is particularly valuable for exploring how integrin alpha5beta1 cooperates with growth factor receptors and oncogenic mutations prevalent in lung adenocarcinoma, and for assessing the contribution of fibronectin-integrin interactions to chemoresistance and angiogenesis. Consequently, the ITGA5 knockout A-549 polyclonal cells enable dissection of integrin-mediated contributions to epithelial-mesenchymal transition, matrix remodeling, and tumor-stromal crosstalk.
Researchers can employ these cells in a variety of experimental paradigms including fibronectin adhesion assays, Transwell migration and Matrigel invasion assays, and analysis of phosphorylation states of FAK (Tyr397) and ERK1/2 by western blotting. Functional studies may encompass cell proliferation assays (e.g., MTT or EdU incorporation), apoptosis detection (e.g., Annexin V staining), and evaluation of MMP-2/9 secretion by zymography. The polyclonal knockout population is suitable for large-scale screening of anti-metastatic compounds, siRNA or cDNA rescue experiments, and co-culture systems modeling tumor-stromal interactions. As an advanced tool for signal transduction and cancer biology research, these ITGA5 knockout A-549 polyclonal cells provide a robust platform for preclinical investigation. For further technical assistance, please contact Ascent Research.
